The choice depends on your genetic peptide profile, tolerability, and clinical response trajectory
Roman P, Carrillo-Trabaln F, Snchez-Labraca N, Caadas F, Estvez AF, Cardona D
Gabe MBN, van der Velden WJC, Gadgaard S, et al
IP teams must reprioritize from late-stage thicket construction to early-stage patent capture and biologic format preference in portfolio decisions
Brands that want to use it for therapeutic purposes may use higher amounts, while brands that want to use it for beauty reasons usually use a mild dose along with antioxidants that work well with it
Lead Researcher Spotlight Professor Frank Ng, PhD Department of Biochemistry and Molecular Biology Monash University, Melbourne, Australia Professor Frank Ng led the pioneering research team that developed AOD-9604 in the 1990s as part of efforts to create a targeted anti-obesity therapeutic derived from human growth hormone